Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details) $ in Thousands |
4 Months Ended | ||
---|---|---|---|
Jun. 30, 2023
USD ($)
seat
shares
|
Mar. 07, 2023
USD ($)
shares
|
Dec. 31, 2022
shares
|
|
Merger with Sesen Bio | |||
Number of board seats | seat | 7 | ||
Entity common stock, shares outstanding immediately after merger | shares | 40,269,576 | 2,217,737 | |
Cash and cash equivalents | $ 37,873 | ||
Marketable securities | 44,588 | ||
Prepaid expenses and other assets | 1,316 | ||
Restricted cash | 30 | ||
Accounts payable and accrued expenses | (3,499) | ||
Total net assets acquired | 80,308 | ||
Less: Transaction costs | (8,264) | ||
Total net assets acquired less transaction costs | $ 72,044 | ||
Carisma Therapeutics Inc. | |||
Merger with Sesen Bio | |||
Severance and personnel costs paid | $ 4,600 | ||
CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc. | |||
Merger with Sesen Bio | |||
Business acquisition percentage of voting interests acquired | 74.20% | ||
Entity common stock, shares outstanding immediately after merger | shares | 40,254,666 |
X | ||||||||||
- Definition The amount of restricted cash from business combination. No definition available.
|
X | ||||||||||
- Definition Number of Board Members No definition available.
|
X | ||||||||||
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of assets acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|